Sign in

dairegannon.bsky.social

@dairegannon.bsky.social
42 followers 46 following 3 posts

Postdoctoral researcher at WEHI

PostsRepliesMedia
Reposted by @dairegannon.bsky.social
Mel Eckersley-Maslin @meleckmas.bsky.social · 22/03/2026
Delighted to share the lab's latest led by superstar Janith and funded by @snowmedical.bsky.social. What happens when embryonic factors are reawakened in cancers? We uncovered how DPPA2/4 amplify chromatin states in non-small cell lung cancer 🧬🔬🧪 genesdev.cshlp.org/content/earl... Tutorial 👇 (1/8)
genesdev.cshlp.org
Embryonic stem cell factors DPPA2/4 amplify active H3K4me3–H2AK119ub chromatin domains in non-small cell lung cancer
A biweekly scientific journal publishing high-quality research in molecular biology and genetics, cancer biology, biochemistry, and related fields
13115
Reposted by @dairegannon.bsky.social
Chen Davidovich @davidovichlab.bsky.social · 04/03/2026
1/ 🧵 In our new paper, we show that JARID2 and PALI1 mimic H3K27me3 to antagonise PRC2. www.cell.com/molecular-ce...
cell.com
Accessory subunits of PRC2 mimic H3K27me3 to restrict the spread of Polycomb domains
Some proteins mimic the repressive mark H3K27me3, but the physiological relevance of this phenomenon was unclear. Agius et al. show that the PRC2 subunits JARID2 and PALI1 mimic H3K27me3 to antagonize...
16025
Reposted by @dairegannon.bsky.social
Adrian Bracken @adrianbracken.bsky.social · 31/10/2025
1/ 🚀 AEBP2 isn’t what we thought. You were told that AEBP2 promotes PRC2 activity on chromatin. We found the opposite: the most prevalent AEBP2 isoform inhibits PRC2 activity. 👉 surl.li/cgwqcq A thread 🧵
64116
Reposted by @dairegannon.bsky.social
Eric Conway @conwayer1.bsky.social · 03/11/2025
We are delighted that @genesdev.bsky.social have selected our (w/ @adrianbracken.bsky.social) Weaver syndrome paper artwork as the November cover! This piece was made by my incredibly talented niece, Gina 'Dna Vinci' Ronan. @ucddublin.bsky.social @tcddublin.bsky.social @ucd-sbbs.bsky.social
1155
Reposted by @dairegannon.bsky.social
Australasian Epigenetic Alliance (AEpiA) @aepia.bsky.social · 20/10/2025
Congratulations to the winners of the 2025 AEpiA Emma Whitelaw Publication Award! 🧬 1st place: @shellainasci.bsky.social 🧬 2nd place: @victoriasugrue.bsky.social 🧬 3rd place: @dairegannon.bsky.social This award recognises outstanding publications by ECRs in the field of epigenetics.
1134
Reposted by @dairegannon.bsky.social
Dan Angelov @dr-chromatin.bsky.social · 17/10/2025
Absolutely delighted to share our preprint, using functional genomics to uncover a novel dependency in lymphoma that can overcome resistance to targeted therapy. Grateful to co-first author @jamesnolan.bsky.social and co-senior authors @conwayer1.bsky.social and @adrianbracken.bsky.social see👇
053
Reposted by @dairegannon.bsky.social
James Nolan @jamesnolan.bsky.social · 17/10/2025
🧵1/Exciting news in cancer epigenetics! Our latest research, "AEBP2-Directed H3K27me2 Defines a Specific Vulnerability in EZH2-mutant Lymphoma", is now available on www.biorxiv.org/content/10.1.... Here's a thread summarizing our findings!👇 #CancerResearch #Epigenetics #Chromatin #Lymphoma
biorxiv.org
AEBP2-Directed H3K27me2 Defines a Specific Vulnerability in EZH2-mutant Lymphoma
The catalytic subunit of Polycomb Repressive Complex 2 (PRC2), EZH2, is recurrently mutated in 25% of diffuse large B-cell lymphomas (DLBCL), causing increased H3K27me3 and decreased H3K27me2 levels. ...
12310
dairegannon.bsky.social @dairegannon.bsky.social · 06/06/2025
Great to see @jongminkmg.bsky.social’s preview of our work in @cp-molcell.bsky.social today! www.cell.com/molecular-ce...
cell.com
Not all CBXs are created equal: A role for the disordered central region of CBX4 in pediatric glioma
In this issue, Lagan et al.1 apply genome-wide and tiling-scan CRISPR screens to uncover a key role for CBX4 and its central region in promoting the growth of diffuse midline glioma cells bearing the ...
142
Reposted by @dairegannon.bsky.social
Molecular Cell @cp-molcell.bsky.social · 21/05/2025
Online Now: A specific form of cPRC1 containing CBX4 is co-opted to mediate oncogenic gene repression in diffuse midline glioma Online now:
dlvr.it
A specific form of cPRC1 containing CBX4 is co-opted to mediate oncogenic gene repression in diffuse midline glioma
Lagan, Gannon, et al. reveal that H3K27M-DMGs depend on a specific form of cPRC1 containing CBX4 and PCGF4. H3K27M alters H3K27me3 distribution, causing increased binding of CBX4-PCGF4-cPRC1 and oncogenic gene repression. CBX4’s ability to read H3K27me3 and to form a specific cPRC1 complex with PCGF4 makes it essential in DMG.
065
dairegannon.bsky.social @dairegannon.bsky.social · 21/05/2025
Our work identifying CBX4 as a potential therapeutic target for diffuse midline glioma has just been published in Molecular Cell! Check out co-first author @eimearlagan.bsky.social’s overview below.
071